GB9808327D0 - Antidiotypic compounds - Google Patents

Antidiotypic compounds

Info

Publication number
GB9808327D0
GB9808327D0 GBGB9808327.2A GB9808327A GB9808327D0 GB 9808327 D0 GB9808327 D0 GB 9808327D0 GB 9808327 A GB9808327 A GB 9808327A GB 9808327 D0 GB9808327 D0 GB 9808327D0
Authority
GB
United Kingdom
Prior art keywords
compounds
antidiotypic
gbs
oligopeptide
eliciting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9808327.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Priority to GBGB9808327.2A priority Critical patent/GB9808327D0/en
Publication of GB9808327D0 publication Critical patent/GB9808327D0/en
Priority to CA2325566A priority patent/CA2325566C/en
Priority to US09/673,867 priority patent/US6676938B1/en
Priority to PCT/IB1999/000799 priority patent/WO1999054457A1/en
Priority to DE69940545T priority patent/DE69940545D1/de
Priority to EP99914725A priority patent/EP1071763B1/en
Priority to JP2000544789A priority patent/JP4446601B2/ja
Priority to AT99914725T priority patent/ATE425251T1/de
Priority to US10/703,886 priority patent/US6900302B2/en
Priority to JP2009123637A priority patent/JP2009179645A/ja
Priority to CY20091100604T priority patent/CY1109140T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4233—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-bacterial Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB9808327.2A 1998-04-20 1998-04-20 Antidiotypic compounds Ceased GB9808327D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB9808327.2A GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds
AT99914725T ATE425251T1 (de) 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen
DE69940545T DE69940545D1 (de) 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen
US09/673,867 US6676938B1 (en) 1998-04-20 1999-04-20 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group B streptococcal carbohydrates
PCT/IB1999/000799 WO1999054457A1 (en) 1998-04-20 1999-04-20 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
CA2325566A CA2325566C (en) 1998-04-20 1999-04-20 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
EP99914725A EP1071763B1 (en) 1998-04-20 1999-04-20 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
JP2000544789A JP4446601B2 (ja) 1998-04-20 1999-04-20 Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物
US10/703,886 US6900302B2 (en) 1998-04-20 2003-11-07 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group B streptococcal carbohydrates
JP2009123637A JP2009179645A (ja) 1998-04-20 2009-05-21 Ｂ群連鎖球菌の糖質を免疫学的に模倣する抗イディオタイプ抗体を含むワクチン処方物
CY20091100604T CY1109140T1 (el) 1998-04-20 2009-06-09 Τυποποιησεις εμβολιων που περιλαμβανουν αντιιδιοτυπικα αντισωματα τα οποια μιμουνται ανοσολογικα υαδατανθρακες των στρεπτοκοκκων ομαδας β

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9808327.2A GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds

Publications (1)

Publication Number Publication Date
GB9808327D0 true GB9808327D0 (en) 1998-06-17

Family

ID=10830608

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9808327.2A Ceased GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds

Country Status (9)

Country Link
US (2) US6676938B1 (enExample)
EP (1) EP1071763B1 (enExample)
JP (2) JP4446601B2 (enExample)
AT (1) ATE425251T1 (enExample)
CA (1) CA2325566C (enExample)
CY (1) CY1109140T1 (enExample)
DE (1) DE69940545D1 (enExample)
GB (1) GB9808327D0 (enExample)
WO (1) WO1999054457A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027695A1 (de) * 1999-05-27 2001-04-19 Max Delbrueck Centrum Vakzine gegen konformationsabhängige Antigene sowie gegen Antigene, die keine oder nicht ausschließlich Proteine oder Peptide sind
ES2330083T3 (es) * 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
AU2003260102A1 (en) * 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
US20090104218A1 (en) * 2004-12-22 2009-04-23 J. Craig Venter Institute Group B Streptococcus
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
WO2008108830A2 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
JP5653215B2 (ja) 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
EP2537857B1 (en) * 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3773348B1 (en) 2018-04-10 2025-04-02 Alps Holding Llc Spinal interbody cage comprising top and bottom faces with mesh structures, pillars and slots

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
WO1997045449A1 (en) * 1996-05-29 1997-12-04 Derek Nigel John Hart Dendritic cell receptor
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6444787B1 (en) * 1997-12-31 2002-09-03 Research Development Institute, Inc. Method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine

Also Published As

Publication number Publication date
EP1071763B1 (en) 2009-03-11
CY1109140T1 (el) 2014-07-02
JP2002512026A (ja) 2002-04-23
ATE425251T1 (de) 2009-03-15
CA2325566C (en) 2011-02-08
EP1071763A1 (en) 2001-01-31
DE69940545D1 (de) 2009-04-23
JP2009179645A (ja) 2009-08-13
WO1999054457A1 (en) 1999-10-28
US20040101536A1 (en) 2004-05-27
US6900302B2 (en) 2005-05-31
US6676938B1 (en) 2004-01-13
JP4446601B2 (ja) 2010-04-07
CA2325566A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
GB9808327D0 (en) Antidiotypic compounds
IS5329A (is) Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
BG101995A (en) Saponin and sterol-containing vaccines
AU9094191A (en) Recombinant avirulent salmonella antifertility vaccines
MY125202A (en) Vaccine
ATE188508T1 (de) Impfstoffe gegen diphtherietoxin
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ITRM920256A1 (it) Valvola di mandata per compressore alternativo.
EP0866133A3 (en) A group b streptococcus vaccine
DE69713408D1 (de) Streptococcus equi Impstoff
NO910656L (no) Sperrevaeske-tetningsanordning for turbokompressor.
DE69726712T2 (de) Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
EP0888124A4 (en) Immunogenic assemblies of Porphyromonas Gingivalis peptides and their methods
AU3645595A (en) Synthetic peptides and vaccines comprising same
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
WO1998039450A3 (de) Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen
IT1262269B (it) Macchina confezionatrice, in particolare macchina impacchettatrice, di sigarette o simili.
NL300112I2 (nl) Vaccin tegen dermatomycosis.
NO910655D0 (no) Sperrevaeske-tetningsanordning for turbokompressor.
FI911973A0 (fi) Traodaktigt hemagglutinin av b. pertussis-bacill.
ITGE940094A0 (it) Macchina impacchettatrice per oggetti astiformi delicati, in particolare per sigarette, o simili.
WO2002041921A3 (en) Compositions for protection against bovine viral diseases
FR2715304B1 (fr) Vaccin anti-allergique.
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)